Report on Women’s and Children’s Services Group OB Clinical Work Group Nashville, TN March 17-18, 2011 Clinical Protocols Blood Pressure Management of Severe Intrapartum or Postpartum Hypertension VBAC HCA Policy Postpartum hemorrhage Management of Prolonged Second Stage of Labor Magnesium for fetal neuroprotection Misoprostol labor induction Group B Strep Protocol Blood Pressure Management of Severe Intrapartum or Postpartnm Hypertension systolic blood pressure is ≥ 160 mmHg OR the diastolic blood pressure is ≥ 110 mmHg Labetalol or hydralazine option If either blood pressure criteria is exceeded after 3 doses then MFM , anesthesia or medicine consultation 4 5 VBAC HCA Policy Patients with more than 1 cesarean, an unknown scar type, a baby with an estimated fetal weight > 4000 g or in whom labor induction is contemplated require additional counseling regarding an increased risk of rupture and a decreased chance of success with a trial of labor. This counseling should include: with > 1 prior cesarean, the risk of rupture may be as high as 4%. With an unknown scar type, the risk may be as high as 10% if the scar is vertical. With a macrosomic infant, or with oxytocin induction, the risk of rupture is increased slightly. Postpartum hemorrhage If the estimated blood loss by any provider (OB, Anesthesia or RN ) exceeds 1500 ml OR whenever the systolic pressure is below 90 mmHg OR the diastolic pressure is below 50 mmHg in a bleeding patient 2 OB physicians are notified and required to personally evaluate the patient and both write notes in the chart. 8 9 Management of Prolonged Second Stage of Labor Magnesium for fetal neuroprotection 12 Misoprostol Labor Induction P.o. option – 25mcg Preterm Labor Assessment Cervical Length Fetal Fibronectin Both 15 16 17 Progesterone for Preterm Labor Prophylaxis Makena 1,500 dollars/dose The Clinical Services Group (CSG) has received several questions and comments regarding the substantial price Increase of hydroxyprogesterone caproate Makena®). The aforementioned product was granted approval to Ther-Rx Corporation by the Food and Drug Administration (FDA) on February 4, 2011. Hydroxyprogesterone caproate (Makena®) is an injectable product approved to reduce the risk of preterm birth in women with a singleton pregnancy, who have a history of singleton spontaneous preterm birth1. In 2003, federally funded research demonstrated both 17 alpha-hydroxyprogesterone caproate (17P) in oil, given as an Intramuscular injection once weekly, and micronized vaginal progesterone suppositories (Endometrin®), administered each night, were equally effective in preventing preterm births in the above-mentioned population2,3,4. Prior to approval of hydroxyprogesterone caproate (Makena®), 17P has been widely available as a prescription product at compounding pharmacies. Hydroxyprogesterone caproate (Makena®) is a manufactured version of the identical compounded drug, 17P, with the same medical indications for use. If used, these medications are typically initiated at a gestational age of 16 to 20 weeks. Therefore, use of the above product(s) can approach 20 weeks’ duration. The primary reason for recent controversy revolves around the significant price increase of the manufactured product (Makena’s® actual wholesale price (AWP) is $690/week; $13,800/course) versus the compounded product (17P is approximately 15/week; $300/course). Ther-RX Corporation announced on April 1, 2011 that the list price of Makena price would be reduced by 55% to $690 per injection. CSG is aware of the “cease and desist” letters sent to many compounding pharmacies by Ther-Rx Corporation, threatening FDA enforcement action related to the compounded versions of hydroxyprogesterone caproate. However, on March 30, 2011, the FDA released a statement indicating that the above statement, made by Ther-Rx Corporation, is incorrect. The FDA, according to the March 30 statement, will not exercise its authority to prevent pharmacies from Producing “compounded” versions of the drug unless evidence emerges that patient Safety was at risk.5 At this time, compounding pharmacies may continue to compound versions of hydroxyprogesterone caproate, as long as the Food, Drug and Cosmetic Act (FD&C Act) is followed in accordance with the law. The FD&C Act, Application of Federal Law to Practice of Pharmacy Compounding, states that compounding may occur if the licensed pharmacist or licensed physician do not compound regularly or in inordinate amounts (manufacture) any drug products that are essentially copies of a commercially available drug.6 Therefore, Compounding pharmacies may choose to cease compounding hydroxyprogesterone caproate or they may choose to create a different version of the product. The latter may involve alterations to the product, including, but not limited to, different vehicles, preservative-free preparation and/or single-use vials. The active chemical, hydroxyprogesterone caproate, will remain the same. CSG, along with members of the Obstetric Clinical Workgroup, have worked together to create the following guidance statements. It is our recommendation that facilities should: Discuss hydroxyprogesterone caproate (Makena®) use with both the Pharmacy and Therapeutics (P & T) Committee and the Obstetrics and Gynecology Committee. Decide upon formulary versus non-formulary status. Inform Obstetricians of the patient-assistance programs offered by Ther-Rx Corporation. This information may be useful for the general outpatient population. Inform Obstetricians of compounded versions of the product. These versions may be purchased, on an outpatient basis, from specialized compounding pharmacies. Decisions should be made by appropriate individuals regarding if compounded products, purchased outside of the institution, are allowed. Factors to consider include, but are not limited to, verification of the product and compounding pharmacy. Discuss addition of micronized vaginal progesterone suppositories (Endometrin®) to the hospital formulary as an acceptable alternative to the injection. Micronized vaginal progesterone suppositories (Endometrin®) have an AWP of $7.50/day; $1050/course, where a course of therapy is equal to 140 days (20 weeks) in duration. Continue our attempts to optimize the management of preterm labor. Progesterone for Preterm Labor Prophylaxis Alternate options 1 Micronized vaginal suppositories 200 mg q hs 2 Hydroxyprogesterone caproate in sesamie oil Postpartum Readmission Rate within 42 Days of Delivery Phone call triage system 1 & 3 days post discharge AirStrip OB Use it or lose it 228$/mo per ob Core Measures No Elective Deliveries Prior TO 39 Weeks Cesarean Section – Nulliparous women with a term, singleton baby in a vertex position delivery by cesarean section Antenatal Steroids – full course 24-32 weeks Health Care-Associated Bloodstream Infections in Newborns Exclusive Breast Milk Feeding Draft of Proposed Score Card 26 EMR is coming Competency Maintenance Modules 2011 HCA Frequency of Adverse Outcomes 29 30